Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Shares Outstanding (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Shares Outstanding for 12 consecutive years, with $114.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 2.89% to $114.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $114.8 million through Dec 2025, up 2.89% year-over-year, with the annual reading at $114.8 million for FY2025, 2.89% up from the prior year.
  • Shares Outstanding hit $114.8 million in Q4 2025 for Viking Therapeutics, up from $112.4 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $114.8 million in Q4 2025 to a low of $76.7 million in Q2 2022.
  • Historically, Shares Outstanding has averaged $94.8 million across 5 years, with a median of $100.0 million in 2023.
  • Biggest five-year swings in Shares Outstanding: decreased 1.98% in 2022 and later surged 38.97% in 2024.
  • Year by year, Shares Outstanding stood at $78.2 million in 2021, then grew by 0.01% to $78.3 million in 2022, then grew by 27.93% to $100.1 million in 2023, then rose by 11.45% to $111.6 million in 2024, then increased by 2.89% to $114.8 million in 2025.
  • Business Quant data shows Shares Outstanding for VKTX at $114.8 million in Q4 2025, $112.4 million in Q3 2025, and $112.3 million in Q2 2025.